Typical traditional probiotics lactobacilli and bifidobacteria are gaining great interest to be developed as living diagnostics and therapeutics for improving human health. However, the mechanistic basis underlying their inherent health beneficial property remain incompletely understood which can slow down the translational pipeline in the functional food and pharmaceutical field. Efficient genome editing will advance the understanding of the molecular mechanism of the probiotics' physiological properties and their interaction with the host and the host microbiota, thereby further promote the development of next-generation designer probiotics with improved robustness and tailored functionalities. With the expansion of genome editing strategies such as CRISPR-Cas-based tools and IPSD assisted genome engineering as well as other synthetic biology technologies, the research and application of these health-promoting bacteria for the food and pharmaceutical industry will be further enhanced.

典型的传统益生菌乳酸杆菌和双歧杆菌引起了人们极大的兴趣，它们被开发为改善人类健康的活体诊断和治疗方法。然而，其固有的有益健康特性的机制基础仍未完全了解，这可能会减慢功能性食品和制药领域的转化过程。有效的基因组编辑将促进对益生菌生理特性及其与宿主和宿主微生物群相互作用的分子机制的理解，从而进一步促进具有更高稳健性和定制功能的下一代设计益生菌的开发。